Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

118.64 +0.35 (+0.30%)
Official Closing Price Updated: 7:00 PM EDT, Sep 18, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 11,139,556
Open 118.20
Bid (Size) 118.69 (9)
Ask (Size) 119.28 (10)
Prev. Close 118.29
Today's Range 117.87 - 119.38
52wk Range 99.14 - 134.63
Shares Outstanding 2,531,374,696
Dividend Yield 2.46%
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Merck's Keytruda Secures First FDA-Approval For Rare Form Aggressive Cancer
The FDA has approved Merck's Keytruda (pembrolizumab) in combination with pemetrexed and platinum chemotherapy for first-line treatment of advanced or metastatic malignant pleural mesothelioma. 
Via Benzinga
Exposures Product Safety
Behind the Scenes of Merck & Co's Latest Options Trends
Via Benzinga

Performance

YTD
+4.77%
+4.77%
1 Month
+3.69%
+3.69%
3 Month
-7.31%
-7.31%
6 Month
-2.91%
-2.91%
1 Year
+10.04%
+10.04%

More News

Read More
NYSE:MRK: good value for what you're paying.
Via Chartmill
This Company Generates No Revenue and Its Market Cap Is Over $20 Billion. Here's Why That Valuation May Not Be All That Ridiculous.
Via The Motley Fool
FDA Approves Merck’s KEYTRUDA® (pembrolizumab) Plus Pemetrexed and Platinum Chemotherapy as First-Line Treatment for Adult Patients With Unresectable Advanced or Metastatic Malignant Pleural Mesothelioma (MPM)
From Merck & Co., Inc.
Via Business Wire
Competitor Analysis: Evaluating Merck & Co And Competitors In Pharmaceuticals Industry
Via Benzinga
A Closer Look at 8 Analyst Recommendations For Merck & Co
Via Benzinga
Where Will Merck Stock Be in 5 Years?
Via The Motley Fool
Prediction: These Could Be the Best-Performing Biotech Stocks Through 2030
Via The Motley Fool
How BioNTech, Up 25% Over Four Days, Is Riding Summit's Coattails To A Recovery
Via Investor's Business Daily
Merck/Daiichi Sankyo Partnered Lung Cancer Candidate Meets Primary Goal In Late-Stage Study
Via Benzinga
Patritumab Deruxtecan Demonstrated Statistically Significant Improvement in Progression-Free Survival Versus Doublet Chemotherapy in Patients with Locally Advanced or Metastatic EGFR-Mutated Non-Small Cell Lung Cancer in HERTHENA-Lung02 Phase 3 Trial
From Daiichi Sankyo
Via Business Wire
Merck & Co Unusual Options Activity
Via Benzinga
Moderna’s Recent Drop: 4 Reasons Bulls See Opportunity
Via MarketBeat
Exposures COVID-19 Product Safety
NuCana Resistant Melanoma Treatment Data Shows Providing Some Relief After Disappointing Colorectal Cancer Data, Stock Surges
Via Benzinga
Merck Scores Two Key Victories With Keytruda In Women's Cancers
Via Investor's Business Daily
KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as Single Agent After Surgery Reduced Risk of Death by More Than One-Third (34%) Versus Neoadjuvant Chemotherapy in High-Risk Early-Stage Triple-Negative Breast Cancer (TNBC)
From Merck & Co., Inc.
Via Business Wire
Ten-Year Data for Merck’s KEYTRUDA® (pembrolizumab) Demonstrates Sustained Overall Survival Benefit Versus Ipilimumab in Advanced Melanoma
From Merck & Co., Inc.
Via Business Wire
KEYTRUDA® (pembrolizumab) Plus LENVIMA® (lenvatinib) in Combination With Transarterial Chemoembolization Significantly Improved Progression-Free Survival Compared to TACE Alone in Patients With Unresectable, Non-Metastatic Hepatocellular Carcinoma
From Merck & Co., Inc.
Via Business Wire
Merck’s KEYTRUDA® (pembrolizumab) Plus Chemoradiotherapy (CRT) Reduced Risk of Death by 33% Versus CRT Alone in Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
From Merck & Co., Inc.
Via Business Wire
MarketBeat Week in Review – 9/9 - 9/13
Via MarketBeat
Topics Economy
Exposures Economy Interest Rates
KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy Significantly Improved Overall Survival (OS) Versus Trastuzumab and Chemotherapy Alone in First-Line Treatment of Patients With HER2-Positive Advanced Gastric or GEJ Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Moderna Faces Analyst Downgrades Amid Revised R&D Restructured Strategy and Delayed Profitability Target
Via Benzinga
Time To Invest And Or Trade In Bio-Tech Stocks?
Via Talk Markets
Topics ETFs
Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day
Via Investor's Business Daily
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.